Drug Trial Radar · NCT03547271
Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe
Last checked: Nov 20, 2026Latest source record: Mar 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,660
Actual
Start
Dec 14, 2018
Primary completion
May 17, 2023
Study completion May 24, 2023
Sponsor
- Lead sponsor
- Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
- Sponsor type
- Industry
- First posted
- Jun 6, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 42 days, up to 89 days
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Primary objective: This study aimed to demonstrate the non-inferiority of the antibody response against meningococcal serogroups A, C, Y, and W following the administration of a 3-dose series of MenACYW conjugate vaccine compared to a 3-dose series of a licensed meningococcal vaccine when each vaccine was given concomitantly with routine pediatric vaccines (10-valent pneumococcal vaccine and diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and Haemophilus influenzae type b \[DTaP-IPV-HB-Hib vaccine\]) to infants and toddlers 6 weeks to 18 months old Secondary objectives: This study aimed to demonstrate the non-inferiority of the antibody (Ab) response against meningococcal serogroups A, C, Y, and W following the administration of 2 doses in infancy of MenACYW conjugate vaccine compared to 2 doses of a licensed meningococcal vaccine when each vaccine was given concomitantly with routine pediatric vaccines (10-valent pneumococcal vaccine and DTaP-IPV-HB-Hib vaccine) to infants and toddlers 6 weeks to 18 months old. \- This study aimed to describe the Ab responses against meningococcal groups A, C, Y, and W and the antigens of the routine pediatric vaccines administered in the study.
Conditions
- Meningococcal Infections
Interventions
MenACYW conjugate vaccineBiological
Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid conjugate vaccine, 0.5 mL, intramuscular
Meningococcal group A, C, W-135, and Y conjugate vaccineBiological
Meningococcal group A, C, W-135, and Y conjugate vaccine, 0.5 mL, intramuscular
DTaP-IPV-HB-Hib vaccineBiological
Diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and Haemophilus influenzae type b vaccine
Pneumococcal vaccine (13-valent)Biological
Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed)
Pneumococcal vaccine (10-valent)Biological
Pneumococcal polysaccharide conjugate vaccine (10-valent, adsorbed)
MMR vaccineBiological
Measles, mumps, and rubella vaccine
Primary outcomes
What the sponsor says the trial is designed to measure.
- Groups 1 and 2: Geometric Mean Titers (GMTs) Against Meningococcal Serogroups A, C, W, and YTime frame: At 30 days post Dose 3 [12 to 18 months of age (MoA)]
Locations
33 sites in 7 countries. Site status is shown where the registry gives one.
Investigational Site Number : 2031006
Chlumec nad Cidlinou, Czechia
Investigational Site Number : 2031013
Domažlice, Czechia
Investigational Site Number : 2031010
Jindřichův Hradec, Czechia
Investigational Site Number : 2031012
Jindřichův Hradec, Czechia
Investigational Site Number : 2031003
Ostrava, Czechia
Investigational Site Number : 2031008
Ostrava-hrabuvka, Czechia
Investigational Site Number : 2031009
Pardubice, Czechia
Investigational Site Number : 2031005
Pardubice, Czechia
Investigational Site Number : 2031007
Smiřice, Czechia
Investigational Site Number : 2462007
Espoo, Finland
Investigational Site Number : 2462003
Helsinki, Finland
Investigational Site Number : 2462004
Helsinki, Finland
Investigational Site Number : 2462001
Jarvenpaa, Finland
Investigational Site Number : 2462006
Kokkola, Finland
Investigational Site Number : 2462005
Oulu, Finland
Investigational Site Number : 2462002
Pori, Finland
Investigational Site Number : 2462009
Seinäjoki, Finland
Investigational Site Number : 2462010
Tampere, Finland
Investigational Site Number : 2462008
Turku, Finland
Investigational Site Number : 3803002
Milan, Italy
Investigational Site Number : 6167003
Siemianowice Śląskie, Poland
Investigational Site Number : 6167006
Torun, Poland
Investigational Site Number : 6167002
Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Poland
Investigational Site Number : 6167004
Trzebnica, Lower Silesian Voivodeship, Poland
Investigational Site Number : 6424003
Brasov, Romania
Investigational Site Number : 6424001
Bucaresti, Romania
Investigational Site Number : 6424002
Calarasi, Romania
Investigational Site Number : 6424006
Caracal, Romania
Investigational Site Number : 7245002
Madrid, Spain
Investigational Site Number : 7245001
Santiago de Compostela, Spain
Investigational Site Number : 7245006
Seville, Spain
Investigational Site Number : 7245003
Madrid, Madrid, Comunidad de, Spain
Investigational Site Number : 7526001
Umeå, Sweden
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.